Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anaptysbio (ANAB) Non Operating Income (2016 - 2025)

Anaptysbio filings provide 10 years of Non Operating Income readings, the most recent being -$3000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 100.02% year-over-year to -$3000.0, compared with a TTM value of -$24.2 million through Dec 2025, down 247.08%, and an annual FY2025 reading of $5.4 million, up 38685.71% over the prior year.
  • Non Operating Income hit -$3000.0 in Q4 2025 for Anaptysbio, up from -$12.4 million in the prior quarter.
  • The five-year high for Non Operating Income was $18.2 million in Q4 2024, with the low at -$13.6 million in Q4 2022.
  • Median Non Operating Income over the past 5 years was $1500.0 (2022), compared with a mean of -$1.4 million.
  • The sharpest move saw Non Operating Income crashed 4088.66% in 2022, then skyrocketed 22816.25% in 2024.
  • Year by year, Non Operating Income stood at -$1.4 million in 2021, then crashed by 882.04% to -$13.6 million in 2022, then surged by 99.41% to -$80000.0 in 2023, then soared by 22816.25% to $18.2 million in 2024, then tumbled by 100.02% to -$3000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$3000.0, -$12.4 million, and -$11.7 million for Q4 2025, Q2 2025, and Q1 2025 respectively.